The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2−negative metastatic breast cancer: experience from the patient perspective
- 6 August 2014
- journal article
- research article
- Published by Taylor & Francis Ltd in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 14 (6), 929-940
- https://doi.org/10.1586/14737167.2014.949243
Abstract
This study aimed to characterize the impact of metastatic breast cancer (MBC) and cancer treatments on health-related quality of life, treatment satisfaction, and daily productivity from the patient perspective. This was a cross-sectional survey of patients with MBC (USA, n = 200; EU, n = 160). Post-menopausal women aged ≥50 years with hormone receptor positive (HR+), HER2-negative (HER2-) MBC, currently using hormonal therapy (HT) or using chemotherapy (CT) for ≤1 year were recruited. Fifty three percent (n = 191) reported CT and 47% (n = 169) reported HT use. Adjusting for covariates, HT users reported greater health-related quality of life (p < 0.05), greater satisfaction with treatment and better feelings about side-effects (p < 0.001). HT users reported less bother with treatment side-effects (0-5 scale, p < 0.001) and less activity impairment than CT users (p < 0.001). HT was associated with better patient-reported outcomes than CT in first-line MBC management. These findings should be taken into consideration while making treatment decisions for HR+/HER2- MBC.Keywords
This publication has 29 references indexed in Scilit:
- Incidence of Breast Cancer With Distant Involvement Among Women in the United States, 1976 to 2009JAMA, 2013
- Effect of HER2 status on distant recurrence in early stage breast cancerBreast Cancer Research and Treatment, 2012
- Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals Of Oncology, 2012
- The economic burden of metastatic breast cancer: a U.S. managed care perspectiveBreast Cancer Research and Treatment, 2012
- Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)The Lancet Oncology, 2012
- 1st International consensus guidelines for advanced breast cancer (ABC 1)The Breast, 2012
- Clinical and biomarker predictors of side effects from tamoxifenBreast Cancer Research and Treatment, 2011
- International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent ChemotherapyJNCI Journal of the National Cancer Institute, 2009
- The Costs of Treating Breast Cancer in the USPharmacoEconomics, 2009
- Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage Breast CancerJNCI Monographs, 2001